An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models
Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations. Clinical application of istradefylline for the management of other...
Gespeichert in:
| Veröffentlicht in: | Neuropharmacology 2016-11, Vol.110 (Pt A), p.48-58 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 58 |
|---|---|
| container_issue | Pt A |
| container_start_page | 48 |
| container_title | Neuropharmacology |
| container_volume | 110 |
| creator | Ko, Wai Kin D. Camus, Sandrine M. Li, Qin Yang, Jianzhong McGuire, Steve Pioli, Elsa Y. Bezard, Erwan |
| description | Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations. Clinical application of istradefylline for the management of other l-DOPA-induced complications, both motor and non-motor related (i.e. dyskinesia and cognitive impairments), remains to be determined. In this study, acute effects of istradefylline (60–100 mg/kg) alone, or with optimal and sub-optimal doses of l-DOPA, were evaluated in two monkey models of PD (i) the gold-standard 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of parkinsonian and dyskinetic motor symptoms and (ii) the chronic low dose (CLD) MPTP-treated macaque model of cognitive (working memory and attentional) deficits. Behavioural analyses in l-DOPA-primed MPTP-treated macaques showed that istradefylline alone specifically alleviated postural deficits. When combined with an optimal l-DOPA treatment dose, istradefylline increased on-time, enhanced therapeutic effects on bradykinesia and locomotion, but exacerbated dyskinesia. Istradefylline treatment at specific doses with sub-optimal l-DOPA specifically alleviated bradykinesia. Cognitive assessments in CLD MPTP-treated macaques showed that the attentional and working memory deficits caused by l-DOPA were lowered after istradefylline administration. Taken together, these data support a broader clinical use of istradefylline as an adjunct treatment in PD, where specific treatment combinations can be utilised to manage various l-DOPA-induced complications, which importantly, maintain a desired anti-parkinsonian response.
•Istradefylline treatment alleviates postural deficits in MPTP-treated macaques.•Istradefylline with l-DOPA increases on-time but exacerbates dyskinesia.•Istradefylline improves cognition in l-DOPA-treated MPTP-treated macaques.•Istradefylline can be used in PD for treatment of motor and cognitive impairments. |
| doi_str_mv | 10.1016/j.neuropharm.2016.07.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01349218v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390816302982</els_id><sourcerecordid>1821792234</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-9366cc7deefe904e101cf922f9e1d42d71ce47daf9542329d975d534653eb11e3</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhUcIRNPCKyAvWyke_JfxzDJU0CIFkUVZW659h3GYsYPtRJr34UFxSClLVrauz7nf9T1VhSipKaHN-13t4RDDftBxqlmp1ETWhLIX1YK2kmNJGvGyWhDCWsw70l5UlyntCCGipe3r6oJJwQQlbFH9WnsERz0edHbBo9Ajl3LUFvp5HJ0HlCPoPIHPqDxvdfzhfAreaY-mkENE2ltkwnfvsjsCKj5nXE7IeUTxBHmYRyzwfgBfLnTJlnzZ4AwFMcy2_GCOzp4w11-2D9sb_IcGFk3a6J8HKAwLY3pTver1mODt03lVffv08eH2Hm--3n2-XW-wEaTNuONNY4y0AD10REBZlek7xvoOqBXMSmpASKv7biUYZ53t5MquuGhWHB4pBX5V3Zz7DnpU--gmHWcVtFP364061QjlomO0PdKivT5r9zGUSVNWk0sGxlF7CIekaMuoLHAuirQ9S00MKUXon3tTok55qp36l6c65amILDBWrO-eKIfHCeyz8W-ARfDhLChrgqODqJJx4A1YF8FkZYP7P-U3PXS4RQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1821792234</pqid></control><display><type>article</type><title>An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Ko, Wai Kin D. ; Camus, Sandrine M. ; Li, Qin ; Yang, Jianzhong ; McGuire, Steve ; Pioli, Elsa Y. ; Bezard, Erwan</creator><creatorcontrib>Ko, Wai Kin D. ; Camus, Sandrine M. ; Li, Qin ; Yang, Jianzhong ; McGuire, Steve ; Pioli, Elsa Y. ; Bezard, Erwan</creatorcontrib><description>Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations. Clinical application of istradefylline for the management of other l-DOPA-induced complications, both motor and non-motor related (i.e. dyskinesia and cognitive impairments), remains to be determined. In this study, acute effects of istradefylline (60–100 mg/kg) alone, or with optimal and sub-optimal doses of l-DOPA, were evaluated in two monkey models of PD (i) the gold-standard 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of parkinsonian and dyskinetic motor symptoms and (ii) the chronic low dose (CLD) MPTP-treated macaque model of cognitive (working memory and attentional) deficits. Behavioural analyses in l-DOPA-primed MPTP-treated macaques showed that istradefylline alone specifically alleviated postural deficits. When combined with an optimal l-DOPA treatment dose, istradefylline increased on-time, enhanced therapeutic effects on bradykinesia and locomotion, but exacerbated dyskinesia. Istradefylline treatment at specific doses with sub-optimal l-DOPA specifically alleviated bradykinesia. Cognitive assessments in CLD MPTP-treated macaques showed that the attentional and working memory deficits caused by l-DOPA were lowered after istradefylline administration. Taken together, these data support a broader clinical use of istradefylline as an adjunct treatment in PD, where specific treatment combinations can be utilised to manage various l-DOPA-induced complications, which importantly, maintain a desired anti-parkinsonian response.
•Istradefylline treatment alleviates postural deficits in MPTP-treated macaques.•Istradefylline with l-DOPA increases on-time but exacerbates dyskinesia.•Istradefylline improves cognition in l-DOPA-treated MPTP-treated macaques.•Istradefylline can be used in PD for treatment of motor and cognitive impairments.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2016.07.012</identifier><identifier>PMID: 27424102</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adenosine A2 Receptor Antagonists - administration & dosage ; Animals ; Cognition ; Cognition Disorders - drug therapy ; Cognition Disorders - physiopathology ; Cognition Disorders - psychology ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical - methods ; Drug Therapy, Combination ; Dyskinesia, Drug-Induced - drug therapy ; Dyskinesia, Drug-Induced - physiopathology ; Dyskinesia, Drug-Induced - psychology ; Environmental Sciences ; Female ; Hypokinesia - drug therapy ; Hypokinesia - physiopathology ; Hypokinesia - psychology ; Istradefylline ; KW-6002 ; l-DOPA-induced dyskinesia ; Levodopa - administration & dosage ; Levodopa - toxicity ; Life Sciences ; Macaca fascicularis ; Motor Skills Disorders - drug therapy ; Motor Skills Disorders - physiopathology ; Motor Skills Disorders - psychology ; MPTP ; MPTP Poisoning - drug therapy ; MPTP Poisoning - physiopathology ; MPTP Poisoning - psychology ; Parkinson's disease ; Purines - administration & dosage ; Treatment Outcome</subject><ispartof>Neuropharmacology, 2016-11, Vol.110 (Pt A), p.48-58</ispartof><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-9366cc7deefe904e101cf922f9e1d42d71ce47daf9542329d975d534653eb11e3</citedby><cites>FETCH-LOGICAL-c408t-9366cc7deefe904e101cf922f9e1d42d71ce47daf9542329d975d534653eb11e3</cites><orcidid>0000-0001-6427-7357 ; 0000-0002-0410-4638</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuropharm.2016.07.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27424102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01349218$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ko, Wai Kin D.</creatorcontrib><creatorcontrib>Camus, Sandrine M.</creatorcontrib><creatorcontrib>Li, Qin</creatorcontrib><creatorcontrib>Yang, Jianzhong</creatorcontrib><creatorcontrib>McGuire, Steve</creatorcontrib><creatorcontrib>Pioli, Elsa Y.</creatorcontrib><creatorcontrib>Bezard, Erwan</creatorcontrib><title>An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations. Clinical application of istradefylline for the management of other l-DOPA-induced complications, both motor and non-motor related (i.e. dyskinesia and cognitive impairments), remains to be determined. In this study, acute effects of istradefylline (60–100 mg/kg) alone, or with optimal and sub-optimal doses of l-DOPA, were evaluated in two monkey models of PD (i) the gold-standard 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of parkinsonian and dyskinetic motor symptoms and (ii) the chronic low dose (CLD) MPTP-treated macaque model of cognitive (working memory and attentional) deficits. Behavioural analyses in l-DOPA-primed MPTP-treated macaques showed that istradefylline alone specifically alleviated postural deficits. When combined with an optimal l-DOPA treatment dose, istradefylline increased on-time, enhanced therapeutic effects on bradykinesia and locomotion, but exacerbated dyskinesia. Istradefylline treatment at specific doses with sub-optimal l-DOPA specifically alleviated bradykinesia. Cognitive assessments in CLD MPTP-treated macaques showed that the attentional and working memory deficits caused by l-DOPA were lowered after istradefylline administration. Taken together, these data support a broader clinical use of istradefylline as an adjunct treatment in PD, where specific treatment combinations can be utilised to manage various l-DOPA-induced complications, which importantly, maintain a desired anti-parkinsonian response.
•Istradefylline treatment alleviates postural deficits in MPTP-treated macaques.•Istradefylline with l-DOPA increases on-time but exacerbates dyskinesia.•Istradefylline improves cognition in l-DOPA-treated MPTP-treated macaques.•Istradefylline can be used in PD for treatment of motor and cognitive impairments.</description><subject>Adenosine A2 Receptor Antagonists - administration & dosage</subject><subject>Animals</subject><subject>Cognition</subject><subject>Cognition Disorders - drug therapy</subject><subject>Cognition Disorders - physiopathology</subject><subject>Cognition Disorders - psychology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Drug Therapy, Combination</subject><subject>Dyskinesia, Drug-Induced - drug therapy</subject><subject>Dyskinesia, Drug-Induced - physiopathology</subject><subject>Dyskinesia, Drug-Induced - psychology</subject><subject>Environmental Sciences</subject><subject>Female</subject><subject>Hypokinesia - drug therapy</subject><subject>Hypokinesia - physiopathology</subject><subject>Hypokinesia - psychology</subject><subject>Istradefylline</subject><subject>KW-6002</subject><subject>l-DOPA-induced dyskinesia</subject><subject>Levodopa - administration & dosage</subject><subject>Levodopa - toxicity</subject><subject>Life Sciences</subject><subject>Macaca fascicularis</subject><subject>Motor Skills Disorders - drug therapy</subject><subject>Motor Skills Disorders - physiopathology</subject><subject>Motor Skills Disorders - psychology</subject><subject>MPTP</subject><subject>MPTP Poisoning - drug therapy</subject><subject>MPTP Poisoning - physiopathology</subject><subject>MPTP Poisoning - psychology</subject><subject>Parkinson's disease</subject><subject>Purines - administration & dosage</subject><subject>Treatment Outcome</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uEzEUhUcIRNPCKyAvWyke_JfxzDJU0CIFkUVZW659h3GYsYPtRJr34UFxSClLVrauz7nf9T1VhSipKaHN-13t4RDDftBxqlmp1ETWhLIX1YK2kmNJGvGyWhDCWsw70l5UlyntCCGipe3r6oJJwQQlbFH9WnsERz0edHbBo9Ajl3LUFvp5HJ0HlCPoPIHPqDxvdfzhfAreaY-mkENE2ltkwnfvsjsCKj5nXE7IeUTxBHmYRyzwfgBfLnTJlnzZ4AwFMcy2_GCOzp4w11-2D9sb_IcGFk3a6J8HKAwLY3pTver1mODt03lVffv08eH2Hm--3n2-XW-wEaTNuONNY4y0AD10REBZlek7xvoOqBXMSmpASKv7biUYZ53t5MquuGhWHB4pBX5V3Zz7DnpU--gmHWcVtFP364061QjlomO0PdKivT5r9zGUSVNWk0sGxlF7CIekaMuoLHAuirQ9S00MKUXon3tTok55qp36l6c65amILDBWrO-eKIfHCeyz8W-ARfDhLChrgqODqJJx4A1YF8FkZYP7P-U3PXS4RQ</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Ko, Wai Kin D.</creator><creator>Camus, Sandrine M.</creator><creator>Li, Qin</creator><creator>Yang, Jianzhong</creator><creator>McGuire, Steve</creator><creator>Pioli, Elsa Y.</creator><creator>Bezard, Erwan</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-6427-7357</orcidid><orcidid>https://orcid.org/0000-0002-0410-4638</orcidid></search><sort><creationdate>20161101</creationdate><title>An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</title><author>Ko, Wai Kin D. ; Camus, Sandrine M. ; Li, Qin ; Yang, Jianzhong ; McGuire, Steve ; Pioli, Elsa Y. ; Bezard, Erwan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-9366cc7deefe904e101cf922f9e1d42d71ce47daf9542329d975d534653eb11e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adenosine A2 Receptor Antagonists - administration & dosage</topic><topic>Animals</topic><topic>Cognition</topic><topic>Cognition Disorders - drug therapy</topic><topic>Cognition Disorders - physiopathology</topic><topic>Cognition Disorders - psychology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Drug Therapy, Combination</topic><topic>Dyskinesia, Drug-Induced - drug therapy</topic><topic>Dyskinesia, Drug-Induced - physiopathology</topic><topic>Dyskinesia, Drug-Induced - psychology</topic><topic>Environmental Sciences</topic><topic>Female</topic><topic>Hypokinesia - drug therapy</topic><topic>Hypokinesia - physiopathology</topic><topic>Hypokinesia - psychology</topic><topic>Istradefylline</topic><topic>KW-6002</topic><topic>l-DOPA-induced dyskinesia</topic><topic>Levodopa - administration & dosage</topic><topic>Levodopa - toxicity</topic><topic>Life Sciences</topic><topic>Macaca fascicularis</topic><topic>Motor Skills Disorders - drug therapy</topic><topic>Motor Skills Disorders - physiopathology</topic><topic>Motor Skills Disorders - psychology</topic><topic>MPTP</topic><topic>MPTP Poisoning - drug therapy</topic><topic>MPTP Poisoning - physiopathology</topic><topic>MPTP Poisoning - psychology</topic><topic>Parkinson's disease</topic><topic>Purines - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ko, Wai Kin D.</creatorcontrib><creatorcontrib>Camus, Sandrine M.</creatorcontrib><creatorcontrib>Li, Qin</creatorcontrib><creatorcontrib>Yang, Jianzhong</creatorcontrib><creatorcontrib>McGuire, Steve</creatorcontrib><creatorcontrib>Pioli, Elsa Y.</creatorcontrib><creatorcontrib>Bezard, Erwan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ko, Wai Kin D.</au><au>Camus, Sandrine M.</au><au>Li, Qin</au><au>Yang, Jianzhong</au><au>McGuire, Steve</au><au>Pioli, Elsa Y.</au><au>Bezard, Erwan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>110</volume><issue>Pt A</issue><spage>48</spage><epage>58</epage><pages>48-58</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time in Parkinson's disease (PD) patients experiencing motor fluctuations. Clinical application of istradefylline for the management of other l-DOPA-induced complications, both motor and non-motor related (i.e. dyskinesia and cognitive impairments), remains to be determined. In this study, acute effects of istradefylline (60–100 mg/kg) alone, or with optimal and sub-optimal doses of l-DOPA, were evaluated in two monkey models of PD (i) the gold-standard 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of parkinsonian and dyskinetic motor symptoms and (ii) the chronic low dose (CLD) MPTP-treated macaque model of cognitive (working memory and attentional) deficits. Behavioural analyses in l-DOPA-primed MPTP-treated macaques showed that istradefylline alone specifically alleviated postural deficits. When combined with an optimal l-DOPA treatment dose, istradefylline increased on-time, enhanced therapeutic effects on bradykinesia and locomotion, but exacerbated dyskinesia. Istradefylline treatment at specific doses with sub-optimal l-DOPA specifically alleviated bradykinesia. Cognitive assessments in CLD MPTP-treated macaques showed that the attentional and working memory deficits caused by l-DOPA were lowered after istradefylline administration. Taken together, these data support a broader clinical use of istradefylline as an adjunct treatment in PD, where specific treatment combinations can be utilised to manage various l-DOPA-induced complications, which importantly, maintain a desired anti-parkinsonian response.
•Istradefylline treatment alleviates postural deficits in MPTP-treated macaques.•Istradefylline with l-DOPA increases on-time but exacerbates dyskinesia.•Istradefylline improves cognition in l-DOPA-treated MPTP-treated macaques.•Istradefylline can be used in PD for treatment of motor and cognitive impairments.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27424102</pmid><doi>10.1016/j.neuropharm.2016.07.012</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6427-7357</orcidid><orcidid>https://orcid.org/0000-0002-0410-4638</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-3908 |
| ispartof | Neuropharmacology, 2016-11, Vol.110 (Pt A), p.48-58 |
| issn | 0028-3908 1873-7064 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01349218v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adenosine A2 Receptor Antagonists - administration & dosage Animals Cognition Cognition Disorders - drug therapy Cognition Disorders - physiopathology Cognition Disorders - psychology Dose-Response Relationship, Drug Drug Evaluation, Preclinical - methods Drug Therapy, Combination Dyskinesia, Drug-Induced - drug therapy Dyskinesia, Drug-Induced - physiopathology Dyskinesia, Drug-Induced - psychology Environmental Sciences Female Hypokinesia - drug therapy Hypokinesia - physiopathology Hypokinesia - psychology Istradefylline KW-6002 l-DOPA-induced dyskinesia Levodopa - administration & dosage Levodopa - toxicity Life Sciences Macaca fascicularis Motor Skills Disorders - drug therapy Motor Skills Disorders - physiopathology Motor Skills Disorders - psychology MPTP MPTP Poisoning - drug therapy MPTP Poisoning - physiopathology MPTP Poisoning - psychology Parkinson's disease Purines - administration & dosage Treatment Outcome |
| title | An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T06%3A13%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20evaluation%20of%20istradefylline%20treatment%20on%20Parkinsonian%20motor%20and%20cognitive%20deficits%20in%201-methyl-4-phenyl-1,2,3,6-tetrahydropyridine%20(MPTP)-treated%20macaque%20models&rft.jtitle=Neuropharmacology&rft.au=Ko,%20Wai%20Kin%20D.&rft.date=2016-11-01&rft.volume=110&rft.issue=Pt%20A&rft.spage=48&rft.epage=58&rft.pages=48-58&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2016.07.012&rft_dat=%3Cproquest_hal_p%3E1821792234%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1821792234&rft_id=info:pmid/27424102&rft_els_id=S0028390816302982&rfr_iscdi=true |